" class="no-js "lang="en-US"> Alnylam - Medtech Alert
Monday, December 11, 2023
Alnylam | MTA


About Alnylam

Alnylam has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet needs. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA® (vutrisiran) and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.

Related Story

Alnylam & Regeneron Report Positive Data on ALN-APP, an Investigational Therapeutic for Alzheimer’s Disease & Cerebral Amyloid Angiopathy

April 27 2023

Alnylam Pharmaceuticals and Regeneron Pharmaceuticals announced today positive interim results from the ongoing single ascending […]